TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.

Choose your answer: based on the paragraph above can we conclude that "the company wants to sell lots of drugs"?

Options are: I. Yes. II. It's impossible to say. III. No.
I think the answer is
II.